ACADIA Pharmaceuticals ($ACAD) Insider Trading & Smart Money Activity

ACADIA Pharmaceuticals Inc. · Biotechnology · Latest filing Jun 30, 2026

ACADIA Pharmaceuticals Inc. ($ACAD) has 1 insider trade, 7 13F position changes and 3 analyst ratings on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($297.86K), net -$297.86K.

Insider buyers (12 mo)

0

Insider sellers (12 mo)

1

Net insider $ (12 mo)

-$297.86K

Congress trades (12 mo)

0

13F moves on file

7

Analyst ratings on file

3

ACAD insider buying and selling by quarter

Quarter	Insider buys	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0	0 / 0	0 / 0
Q2 2026	0	1 · $297.86K	0 / 0	3 / 4
Q3 2026	0	0	0 / 0	0 / 0
Q4 2026	0	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All ACAD insider, congress, 13F and analyst activity

All Insiders 13F Analysts

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Jun 30, 2026	Analyst	B of A Securities	Reiterates to buy		PT $30		+3.6%	+4.9%			Read
Jun 29, 2026	Analyst	Citigroup	Reiterates to buy		PT $35		+2.3%	+4.5%			Read
Jun 29, 2026	Analyst	Canaccord Genuity	Reiterates to buy		PT $36		+2.3%	+4.5%			Read
Jun 26, 2026	Insider	James KiharaPRINCIPAL ACCOUNTING OFFICER	Sell (Open-market sale) 10b5-1	11.42K sh	$297.86K		+1.8%	+0.3%			—
May 15, 2026	13F	Point72 Asset Management, L.P.	Reduced	-799.39K sh	$65.72M		-1.4%	-0.6%			—
May 15, 2026	13F	Point72 Asset Management, L.P.	Reduced	-799.39K sh	$55.14M		-1.4%	-0.6%			—
May 15, 2026	13F	Caption Management	New	+120.88K sh	$3.08M		-1.4%	-0.6%			Read
May 14, 2026	13F	Rockefeller Capital Management L.P.	Reduced	-85.68K sh	$26.19M		-3.5%	-3.7%			—
May 14, 2026	13F	Rockefeller Capital Management L.P.	Reduced	-85.68K sh	$21.98M		-3.5%	-3.7%			—
May 12, 2026	13F	Jane Street Group	New	+803.26K sh	$20.48M		-5.7%	-1.5%			—
May 12, 2026	13F	Jane Street Group	New	+803.26K sh	$17.18M		-5.7%	-1.5%			—

1W / 1M / 6M = how ACAD moved from the trade or filing date.

Insider trading in ACAD: who is buying and selling

Insider	Role	Trades	Open-market net	Shares held	Last trade
James Kihara	PRINCIPAL ACCOUNTING OFFICER	1	-$297.86K		Jun 26, 2026

Institutions moving ACAD (13F)

• Point72 Asset Management, L.P.2
• Rockefeller Capital Management L.P.2
• Jane Street Group2
• Caption Management1

Analyst ratings on ACAD

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Jun 30, 2026	B of A Securities	Reiterates	buy	$30	+3.6%	+4.9%		Read
Jun 29, 2026	Citigroup	Reiterates	buy	$35	+2.3%	+4.5%		Read
Jun 29, 2026	Canaccord Genuity	Reiterates	buy	$36	+2.3%	+4.5%		Read

Frequently asked questions

Are ACAD insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $297.86K, a net -$297.86K.

What is the latest insider trade in ACAD?

James Kihara, PRINCIPAL ACCOUNTING OFFICER filed a sell (open-market sale) of 11.42K sh worth $297.86K on Jun 26, 2026.

Which institutions changed their ACAD positions?

Recent 13F filers moving the stock include Point72 Asset Management, L.P., Rockefeller Capital Management L.P., Jane Street Group and Caption Management.

Other biotechnology stocks

• $FOLD
• $IOVA
• $MANE
• $CRSP
• $ORKA
• $EWTX
• $PTCT
• $CELC

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.